The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling. Ma Q, Wang S, Xie Z, Shen Y, et al. J Bone Miner Res 2022;37:152-166.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ma Q, Wang S, Xie Z, Shen Y, et al. The SFRP1 Inhibitor WAY-316606 Attenuates Osteoclastogenesis Through Dual Modulation of Canonical Wnt Signaling. J Bone Miner Res 2022;37:152-166.
PMID: 34490916